Disease · MONDO_0001505
Comparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 28
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Prednisone vs Anakinra and Zinc: deaths from any cause | 12 of 73 | 22 of 74 | 147 | NCT04072822 | Trial comparisons |
| Prednisone vs Anakinra and Zinc: Number of Participants With Infections | 20 of 73 | 23 of 74 | 147 | NCT04072822 | Trial comparisons |
| Prednisone vs Anakinra and Zinc: serious adverse events | 41 of 73 | 49 of 74 | 147 | NCT04072822 | Trial comparisons |
| Selonsertib + Prednisolone vs Placebo + Prednisolone: deaths from any cause | 14 of 50 | 9 of 52 | 102 | NCT02854631 | Trial comparisons |
| Selonsertib + Prednisolone vs Placebo + Prednisolone: serious adverse events | 25 of 50 | 21 of 52 | 102 | NCT02854631 | Trial comparisons |
| Canakinumab vs Placebo: Number of Deaths at Day 90 | 2 of 28 | 2 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Variceal Haemorrhage Over 90 Days | 1 of 28 | 1 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Encephalopathy Over 90 Days | 9 of 28 | 6 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Infection Over 90 Days | 6 of 28 | 8 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Sepsis Over 90 Days | 1 of 28 | 1 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Acute Kidney Injury Over 90 Days | 8 of 28 | 4 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Ascites Over 90 Days | 26 of 28 | 21 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: deaths from any cause | 2 of 28 | 2 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Participants With Treatment-related Adverse Events | 0 of 28 | 0 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: serious adverse events | 10 of 28 | 10 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. | 14 of 24 | 10 of 24 | 48 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Participants Presenting Changes in Steatosis Grade (NAS) From Baseline to Day 28 | 15 of 23 | 18 of 23 | 46 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Presence of Megamitochondria (AHHS) From Baseline to Day 28 | 21 of 23 | 19 of 23 | 46 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Degree of Neutrophil Infiltration (AHHS) From Baseline to Day 28 | 21 of 23 | 17 of 23 | 46 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Degree of Fibrosis (AHHS) From Baseline to Day 28 | 23 of 23 | 22 of 23 | 46 | NCT03775109 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001505/comparisons